16 Apr 2024
07:00 CEST |
ARGENX SE |
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
|
20103010 Biotechnology |
Other subject |
27 Mar 2024
07:00 CET |
ARGENX SE |
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
|
20103010 Biotechnology |
Other subject |
26 Mar 2024
21:00 CET |
ARGENX SE |
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
|
20103010 Biotechnology |
Other subject |
26 Mar 2024
07:00 CET |
ARGENX SE |
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
|
20103010 Biotechnology |
Other subject |
07 Mar 2024
22:01 CET |
ARGENX SE |
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
|
20103010 Biotechnology |
Other subject |
29 Feb 2024
07:00 CET |
ARGENX SE |
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
|
20103010 Biotechnology |
Other subject |
26 Feb 2024
07:00 CET |
ARGENX SE |
argenx to Present at Upcoming Investor Conferences
|
20103010 Biotechnology |
Other subject |
22 Feb 2024
07:00 CET |
ARGENX SE |
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
|
20103010 Biotechnology |
Other subject |
20 Feb 2024
07:00 CET |
ARGENX SE |
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
|
20103010 Biotechnology |
Other subject |
18 Jan 2024
07:00 CET |
ARGENX SE |
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
|
20103010 Biotechnology |
Other subject |
08 Jan 2024
07:00 CET |
ARGENX SE |
argenx Highlights 2024 Strategic Priorities
|
20103010 Biotechnology |
Other subject |
02 Jan 2024
07:00 CET |
ARGENX SE |
argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
|
20103010 Biotechnology |
Other subject |
20 Dec 2023
07:00 CET |
ARGENX SE |
argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus
|
20103010 Biotechnology |
Other subject |
28 Nov 2023
07:00 CET |
ARGENX SE |
argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
|
20103010 Biotechnology |
Other subject |
16 Nov 2023
13:40 CET |
ARGENX SE |
argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis
|
20103010 Biotechnology |
Other subject |
01 Nov 2023
07:00 CET |
ARGENX SE |
argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
|
20103010 Biotechnology |
Other subject |
01 Nov 2023
07:00 CET |
ARGENX SE |
argenx to Present at Upcoming Investor Conferences
|
20103010 Biotechnology |
Other subject |
31 Oct 2023
07:00 CET |
ARGENX SE |
argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
|
20103010 Biotechnology |
Other subject |
24 Oct 2023
07:00 CEST |
ARGENX SE |
argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
|
20103010 Biotechnology |
Other subject |
21 Sep 2023
07:00 CEST |
ARGENX SE |
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
|
20103010 Biotechnology |
Other subject |
15 Sep 2023
07:00 CEST |
ARGENX SE |
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
|
20103010 Biotechnology |
Other subject |
30 Aug 2023
07:00 CEST |
ARGENX SE |
argenx to Present at Upcoming Investor Conferences
|
20103010 Biotechnology |
Other subject |
27 Jul 2023
07:00 CEST |
ARGENX SE |
argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update
|
20103010 Biotechnology |
Other subject |
24 Jul 2023
22:30 CEST |
ARGENX SE |
argenx announces closing of global offering
|
20103010 Biotechnology |
Other subject |
20 Jul 2023
07:00 CEST |
ARGENX SE |
argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023
|
20103010 Biotechnology |
Other subject |
19 Jul 2023
23:58 CEST |
ARGENX SE |
argenx announces full exercise of underwriters’ option to purchase additional ADSs
|
20103010 Biotechnology |
Other subject |
19 Jul 2023
03:30 CEST |
ARGENX SE |
argenx raises $1.1 billion in gross proceeds in a global offering
|
20103010 Biotechnology |
Other subject |
17 Jul 2023
22:01 CEST |
ARGENX SE |
argenx announces launch of proposed global offering
|
20103010 Biotechnology |
Other subject |
17 Jul 2023
07:00 CEST |
ARGENX SE |
argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
|
20103010 Biotechnology |
Other subject |
30 Jun 2023
15:39 CEST |
ARGENX SE |
argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
|
20103010 Biotechnology |
Other subject |
21 Jun 2023
00:12 CEST |
ARGENX SE |
argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis
|
20103010 Biotechnology |
Other subject |
20 Jun 2023
07:00 CEST |
ARGENX SE |
argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
|
20103010 Biotechnology |
Other subject |
31 May 2023
07:00 CEST |
ARGENX SE |
argenx to Present at Upcoming Investor Conferences
|
20103010 Biotechnology |
Other subject |
04 May 2023
07:00 CEST |
ARGENX SE |
argenx Reports First Quarter 2023 Financial Results and Provides Business Update
|
20103010 Biotechnology |
Other subject |
03 May 2023
22:01 CEST |
ARGENX SE |
argenx announces results of Annual General Meeting of Shareholders
|
20103010 Biotechnology |
Other subject |
02 May 2023
07:00 CEST |
ARGENX SE |
argenx to Present at BofA Securities 2023 Health Care Conference
|
20103010 Biotechnology |
Other subject |
27 Apr 2023
07:00 CEST |
ARGENX SE |
argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023
|
20103010 Biotechnology |
Other subject |
18 Apr 2023
07:00 CEST |
ARGENX SE |
argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting
|
20103010 Biotechnology |
Other subject |
17 Apr 2023
08:00 CEST |
ARGENX SE |
argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
|
20103010 Biotechnology |
Other subject |
17 Mar 2023
21:01 CET |
ARGENX SE |
argenx Announces Annual General Meeting of Shareholders on May 2, 2023
|
20103010 Biotechnology |
Other subject |
15 Mar 2023
14:25 CET |
ARGENX SE |
argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis
|
20103010 Biotechnology |
Other subject |
02 Mar 2023
07:00 CET |
ARGENX SE |
argenx Announces Planned Transition of Chief Operating Officer
|
20103010 Biotechnology |
Other subject |
02 Mar 2023
07:00 CET |
ARGENX SE |
argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update
|
20103010 Biotechnology |
Other subject |
27 Feb 2023
22:01 CET |
ARGENX SE |
argenx Appoints Steve Krognes to Board of Directors
|
20103010 Biotechnology |
Other subject |
27 Feb 2023
07:00 CET |
ARGENX SE |
argenx to Present at Upcoming Investor Conferences
|
20103010 Biotechnology |
Other subject |
23 Feb 2023
07:00 CET |
ARGENX SE |
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
|
20103010 Biotechnology |
Other subject |
27 Jan 2023
07:00 CET |
ARGENX SE |
argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
|
20103010 Biotechnology |
Other subject |
16 Jan 2023
19:30 CET |
ARGENX SE |
argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
|
20103010 Biotechnology |
Other subject |
09 Jan 2023
07:00 CET |
ARGENX SE |
argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
|
20103010 Biotechnology |
Other subject |
03 Jan 2023
07:00 CET |
ARGENX SE |
argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
|
20103010 Biotechnology |
Other subject |